DIA: Driving Insights to Action
Science:Life Sciences
New horizons opened by personalized (or precision) medicine are also opportunities for combination products, explains Bill Zeruld, a senior Business Development–Digital Strategy executive with Otsuka America Pharmaceuticals, Inc., and a member of the program committee for DIA’s Combination Products Conference. “It’s an exciting time for industry because you start to now have the power of the traditional medicines and traditional medical devices enhanced with the power of digital technology and the underlying data that supports those technologies,” he explains.
Cancer Data Ecosystem Powering Moonshot Relaunch
Complexity Continues to Challenge Clinical Costs
Maximizing Regulatory Resources Across Latin America
Data Intersections Connecting Drug Development with Clinical Care
Sharing Cloud-Based Data as They Emerge: Accumulus Synergy Part 2
Sharing Cloud-Based Data as They Emerge: Accumulus Synergy Part 1
Advanced Tests and Therapies Making Daily Care Anything But Routine
Innovation Without Access Will Never Meet Patient Needs
Three Good Reasons to Use Artificial Intelligence in Pharmacovigilance
EU Regulatory Strategies Shaping and Shaped by Pandemic Response
Telehealth Emerging in Japan’s Clinical Research and Care
Aligned Review Timelines Key to Co-Developing Companion Diagnostics
Early Access Programs Complicating Comparative Data Analyses
New PAHO Report: Strength in Regulatory Reference and Reliance
eLabeling More than Moving from Paper to Digital
RIM Whitepaper V2 and RIM Reference Model: Advancing Regulatory Science
Australia: Growing Clinical Trials Even in Pandemic’s Wake
Remote Tools Keep Japan's Research Moving
DIA Promoting Community, Pushing Back Misinformation
Japan Healthcare 2035: Focus on Basic Science & Economics
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology